Skip to content

Author

C. Nunes-Xavier

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

AXL and enolase 2 associate with therapy resistance to tyrosine kinase inhibitors lenvatinib and cabozantinib in renal cancer cells.

Functional validation confirmed that pharmacological inhibition of AXL and ENO2 effectively reduced cell viability of renal cancer cells, and revealed AXL and ENO2 as promising alternative therapeutic targets in renal cancer.

M. Emaldi, M. Sendino, Javier Muñoz et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.